â– LECTURE OVERVIEW: Lithium carbonate is a highly effective mood stabilizer utilized for bipolar disorder, but it carries a narrow therapeutic index.
â– PHARMACOLOGICAL KINETICS & RENAL FILTERS:
1. Narrow Window: The safe therapeutic index for lithium is narrow: 0.6 to 1.2 mEq/L, with toxic manifestations developing above 1.5 mEq/L.
2. Renal Clearance: Lithium is not metabolized; it is excreted 100% unchanged by the kidneys, handled similarly to sodium.
3. Proximal tubule reabsorption: It is freely filtered by the glomerulus, and approximately 80% is reabsorbed in the proximal convoluted tubule (PCT) alongside sodium.
4. Toxicity Triggers: Any state that reduces glomerular filtration rate or increases proximal sodium and water reabsorption will cause a dangerous accumulation of serum lithium, precipitating toxic levels.
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– CLINICAL CASE SUMMARY:
A 45-year-old patient presented with acute clinical deterioration. Aggressive initial stabilization, molecular monitoring, and specialized pathology screening confirmed the classic disease hallmarks.
[HY-BOARD-1024]
🌟 Dynamic Clinical Key:
Toxicity triggers include dehydration, low-sodium diets, and three classic drug classes: NSAIDs (which block renal prostaglandins to restrict GFR), Thiazide Diuretics (which deplete sodium, driving compensatory PCT reabsorption), and ACE Inhibitors/ARBs. Toxicity presents with severe coarse tremors, ataxia, vomiting, and confusion. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Clinical vigilance during early presentation prevents progression along the severe outcome pathway.